Skip to main content Accessibility help
×
Home

Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis

  • P. Hutton (a1) (a2) and P. J. Taylor (a2)

Abstract

Background

Clinical equipoise regarding preventative treatments for psychosis has encouraged the development and evaluation of psychosocial treatments, such as cognitive behavioural therapy (CBT).

Method

A systematic review and meta-analysis was conducted, examining the evidence for the effectiveness of CBT-informed treatment for preventing psychosis in people who are not taking antipsychotic medication, when compared to usual or non-specific control treatment. Included studies had to meet basic quality criteria, such as concealed and random allocation to treatment groups.

Results

Our search produced 1940 titles, out of which we found seven completed trials (six published). The relative risk (RR) of developing psychosis was reduced by more than 50% for those receiving CBT at every time point [RR at 6 months 0.47, 95% confidence interval (CI) 0.27–0.82, p = 0.008 (fixed-effects only: six randomized controlled trials (RCTs), n = 800); RR at 12 months 0.45, 95% CI 0.28–0.73, p = 0.001 (six RCTs, n = 800); RR at 18–24 months 0.41, 95% CI 0.23–0.72, p = 0.002 (four RCTs, n = 452)]. Heterogeneity was low in every analysis and the results were largely robust to the risk of an unpublished 12-month study having unfavourable results. CBT was also associated with reduced subthreshold symptoms at 12 months, but not at 6 or 18–24 months. No effects on functioning, symptom-related distress or quality of life were observed. CBT was not associated with increased rates of clinical depression or social anxiety (two studies).

Conclusions

CBT-informed treatment is associated with a reduced risk of transition to psychosis at 6, 12 and 18–24 months, and reduced symptoms at 12 months. Methodological limitations and recommendations for trial reporting are discussed.

Copyright

Corresponding author

* Address for correspondence: Dr P. Hutton, Psychosis Research Unit, Psychology Department, Greater Manchester West Mental Health NHS Foundation Trust, Bury New Road, Prestwich, Manchester M25 3BL, UK. (Email: paulhutton@nhs.net)

References

Hide All
Adams, CE, Awad, G, Rathbone, J, Thornley, B (2007). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. Issue 18, Art. No. CD000284.
Addington, J, Epstein, I, Liu, L, French, P, Boydell, KM, Zipursky, RB (2011). A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research 125, 5461.
Amminger, GP, Schafer, MR, Papageorgiou, K, Klier, CM, Cotton, SM, Harrigan, SM, Mackinnon, A, McGorry, PD, Berger, GE (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry 67, 146154.
Bechdolf, A, Müller, H, Stützer, H, Wagner, M, Maier, W, Lautenschlager, M, Heinz, A, de Millas, W, Janssen, B, Gaebel, W, Michel, TM, Schneider, F, Lambert, M, Naber, D, Brüne, M, Krüger-Özgürdal, S, Wobrock, T, Riedel, M, Klosterkötter, J; PREVENT study group (2011). Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophrenia Bulletin 37 (Suppl. 2), S111S121.
Bechdolf, A, Puetzfeld, V, Gross, S, Guettgemanns, J (2010). Cognitive Behavioural Therapy in People at Risk of Psychosis. Huber: Bern, Switzerland.
Bechdolf, A, Wagner, M, Ruhrmann, S, Harrigan, S, Putzfeld, V, Pukrop, R, Brockhaus-Dumke, A, Berning, J, Janssen, B, Decker, P, Bottlender, R, Maurer, K, Moller, HJ, Gaebel, W, Hafner, H, Maier, W, Klosterkotter, J (2012). Preventing progression to first-episode psychosis in early initial prodromal states. British Journal of Psychiatry 200, 2229.
Bechdolf, A, Wagner, M, Veith, V, Ruhrmann, S, Pukrop, R, Brockhaus-Dumke, A, Berning, J, Stamm, E, Janssen, B, Decker, P, Bottlender, R, Moller, HJ, Gaebel, W, Maier, W, Klosterkotter, J (2007). Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Intervention in Psychiatry 1, 7178.
Beck, AT, Grant, PM, Huh, GA, Perivoliotis, D, Chang, NA (2013). Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia. Schizophrenia Bulletin 39, 4351.
Bentall, RP, Morrison, AP (2002). More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. Journal of Mental Health 11, 351365.
Bowie, CR, McLaughlin, D, Carrion, RE, Auther, AM, Cornblatt, BA (2012). Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis. Schizophrenia Research 137, 110117.
Broome, MR, Woolley, JB, Johns, LC, Valmaggia, LR, Tabraham, P, Gafoor, R, Bramon, E, McGuire, PK (2005). Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry 20, 372378.
Bushe, CJ (2011). Systematic reviews – a perspective on benefits and concerns in 2011. Safe, sound and sorted? International Journal of Clinical Practice 65, 921922.
Carpenter, WT (2009). Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophrenia Bulletin 35, 841843.
Carpenter, WT, van Os, J (2011). Should attenuated psychosis syndrome be a DSM-5 diagnosis? American Journal of Psychiatry 168, 460463.
Chuma, J, Mahadun, P (2011). Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria. British Journal of Psychiatry 199, 361366.
Corcoran, CM, First, MB, Cornblatt, B (2010). The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophrenia Research 120, 1622.
Dubitsky, GM, Harris, R, Laughren, T, Hardeman, S (2002). Abilify (aripiprazole) tablets, medical review. US Food and Drug Administration Centre for Drug Evaluation and Research. (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_Abilify.cfm). Accessed 17 June 2010.
Faber, G, Smid, HG, van Gool, AR, Wiersma, D, van den Bosch, RJ (2012). The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry 27, 275280.
French, P, Morrison, AP (2004). Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: A Treatment Approach. Wiley: London.
French, P, Morrison, AP, Walford, L, Knight, A, Bentall, RP (2003). Cognitive therapy for preventing transition to psychosis in high risk individuals: a case series. Behavioural and Cognitive Psychotherapy 31, 5368.
Fusar-Poli, P, Bonoldi, I, Yung, AR, Borgwardt, S, Kempton, MJ, Valmaggia, L, Barale, F, Caverzasi, E, McGuire, P (2012 a). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 69, 220229.
Fusar-Poli, P, Byrne, M, Badger, S, Valmaggia, LR, McGuire, PK (2012 b). Outreach and support in South London (OASIS), 2001–2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. European Psychiatry. Published online: 5 11 2012 . doi:10.1016/j.eurpsy.2012.08.002.
Fusar-Poli, P, Yung, AR (2012). Should attenuated psychosis syndrome be included in DSM-5? Lancet 379, 591592.
Grant, PM, Beck, AT (2009). Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophrenia Bulletin 35, 798806.
Grant, PM, Huh, GA, Perivoliotis, D, Stolar, NM, Beck, AT (2012). Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Archives of General Psychiatry 69, 121127.
Haefner, H, Bechdolf, A, Klosterkoetter, J, Maurer, K (2011). Early Detection and Intervention in Psychosis. A Practice Handbook. Schattauer: Stuttgart.
Hamer, RM, Simpson, PM (2009). Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. American Journal of Psychiatry 166, 639641.
Higgins, JP, Altman, DG, Gotzsche, PC, Juni, P, Moher, D, Oxman, AD, Savovic, J, Schulz, KF, Weeks, L, Sterne, JA (2011 a). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 343, d5928.
Higgins, JPT, Green, S (eds) (2011 b). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011 (www.cochrane-handbook.org).
Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Archives of General Psychiatry 68, 128137.
Hutton, P (2012). Cognitive behavioural therapy for people at high-risk of developing psychosis and not taking antipsychotic medication: a systematic review and exploratory meta-analysis. PROSPERO 2012:CRD42012002260 (www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002260).
Hutton, P, Bowe, S, Parker, S, Ford, S (2011). Prevalence of suicide risk factors in people at ultra-high risk of developing psychosis: a service audit. Early Intervention in Psychiatry 5, 375380.
Ioannidis, JP, Evans, SJ, Gotzsche, PC, O'Neill, RT, Altman, DG, Schulz, K, Moher, D (2004). Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 141, 781788.
Ioannidis, JP, Trikalinos, TA (2007). The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Canadian Medical Association Journal 176, 10911096.
Joy, CB, Adams, CE, Lawrie, SM (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. Issue 18, Art. No. CD003082.
Klingberg, S, Herrlich, J, Wiedemann, G, Wolwer, W, Meisner, C, Engel, C, Jakobi-Malterre, UE, Buchkremer, G, Wittorf, A (2012). Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. Journal of Nervous and Mental Disease 200, 569576.
Klingberg, S, Wittorf, A, Meisner, C, Wolwer, W, Wiedemann, G, Herrlich, J, Bechdolf, A, Muller, BW, Sartory, G, Wagner, M, Kircher, T, Konig, HH, Engel, C, Buchkremer, G (2010). Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: the POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials 11, 123.
Klosterkotter, J, Ruhrmann, S, Schultze-Lutter, F, Salokangas, RK, Linszen, D, Birchwood, M, Juckel, G, Morrison, A, Vazquez-Barquero, JL, Hambrecht, M, von Reventlow, H (2005). The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 4, 161167.
Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM (2009). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry 14, 429447.
Leucht, S, Heres, S, Hamann, J, Kane, JM (2008). Methodological issues in current antipsychotic drug trials. Schizophrenia Bulletin 34, 275285.
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. British Journal of Psychiatry 200, 97106.
Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica. Supplementum 334, 1100.
Mallett, S, Clarke, M (2002). The typical Cochrane review. How many trials? How many participants? International Journal of Technology Assessment in Health Care 18, 820823.
Marshall, M, Rathbone, J (2011). Early intervention for psychosis. Cochrane Database of Systematic Reviews. Issue 15, Art. No. CD004718.
McGlashan, TH, Zipursky, RB, Perkins, D, Addington, J, Miller, T, Woods, SW, Hawkins, KA, Hoffman, RE, Preda, A, Epstein, I, Addington, D, Lindborg, S, Trzaskoma, Q, Tohen, M, Breier, A (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 163, 790799.
McGlashan, TH, Zipursky, RB, Perkins, D, Addington, J, Miller, TJ, Woods, SW, Hawkins, KA, Hoffman, R, Lindborg, S, Tohen, M, Breier, A (2003). The PRIME North America randomized double-bind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research 61, 718.
McGorry, PD, Hickie, IB, Yung, AR, Pantelis, C, Jackson, HJ (2006). Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry 40, 616622.
McGorry, PD, Nelson, B, Phillips, LJ, Yuen, HP, Francey, SM, Thampi, A, Berger, GE, Amminger, GP, Simmons, MB, Kelly, D, Thompson, AD, Yung, AR (2012). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. Journal of Clinical Psychiatry. Published online: 27 11 2012 . doi:10.4088/JCP.12m07785.
McGorry, PD, Yung, AR, Phillips, LJ, Yuen, HP, Francey, S, Cosgrave, EM, Germano, D, Bravin, J, McDonald, T, Blair, A, Adlard, S, Jackson, H (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 59, 921928.
Miller, TJ, McGlashan, TH, Rosen, JL, Cadenhead, K, Cannon, T, Ventura, J, McFarlane, W, Perkins, DO, Pearlson, GD, Woods, SW (2003 a). Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin 29, 703715.
Miller, TJ, Zipursky, RB, Perkins, D, Addington, J, Woods, SW, Hawkins, KA, Hoffman, R, Preda, A, Epstein, I, Addington, D, Lindborg, S, Marquez, E, Tohen, M, Breier, A, McGlashan, TH (2003 b). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the ‘prodromal’ sample. Schizophrenia Research 61, 1930.
Mitchell, AJ, Vancampfort, D, de Herdt, A, Yu, W, de Hert, M (2012). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia Bulletin. Published online: 27 08 2012 . doi:10.1093/schbul/sbs082.
Miyar, J, Adams, CE (2012). Content and quality of 10,000 controlled trials in schizophrenia over 60 years. Schizophrenia Bulletin 39, 226229.
Moncrieff, J, Leo, J (2010). A systematic review of the effects of antipsychotic drugs on brain volume. Psychological Medicine 40, 14091422.
Morrison, AP, Barratt, S (2010). What are the components of CBT for psychosis? A Delphi study. Schizophrenia Bulletin 36, 136142.
Morrison, AP, Bentall, RP, French, P, Walford, L, Kilcommons, A, Knight, A, Kreutz, M, Lewis, SW (2002). Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry. Supplement 43, s78s84.
Morrison, AP, Byrne, R, Bentall, RP (2010). DSM-V and the psychosis risk syndrome: whose best interests would it serve? Psychosis 2, 9699.
Morrison, AP, French, P, Parker, S, Roberts, M, Stevens, H, Bentall, RP, Lewis, SW (2007). Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin 33, 682687.
Morrison, AP, French, P, Stewart, SL, Birchwood, M, Fowler, D, Gumley, AI, Jones, PB, Bentall, RP, Lewis, SW, Murray, GK, Patterson, P, Brunet, K, Conroy, J, Parker, S, Reilly, T, Byrne, R, Davies, LM, Dunn, G (2012 a). Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. British Medical Journal 344, e2233.
Morrison, AP, French, P, Walford, L, Lewis, SW, Kilcommons, A, Green, J, Parker, S, Bentall, RP (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry 185, 291297.
Morrison, AP, Hutton, P, Shiers, D, Turkington, D (2012 b). Antipsychotics: is it time to introduce patient choice? British Journal of Psychiatry 201, 8384.
Morrison, AP, Stewart, SL, French, P, Bentall, RP, Birchwood, M, Byrne, R, Davies, LM, Fowler, D, Gumley, AI, Jones, PB, Lewis, SW, Murray, GK, Patterson, P, Dunn, G (2011). Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. Early Intervention in Psychiatry 5, 2432.
NICE (2009). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary Care and Secondary Care. NICE Clinical Guideline CG82. National Institute for Health and Clinical Excellence (http://publications.nice.org.uk/schizophrenia-cg82).
Nieman, DH, Rike, WH, Becker, HE, Dingemans, PM, van Amelsvoort, TA, de Haan, L, van der Gaag, M, Denys, DA, Linszen, DH (2009). Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. International Journal of Clinical Psychopharmacology 24, 223228.
Niemeyer, H, Musch, J, Pietrowsky, R (2012). Publication bias in meta-analyses of the efficacy of psychotherapeutic interventions for schizophrenia. Schizophrenia Research 138, 103112.
O'Brien, MP, Zinberg, JL, Bearden, CE, Daley, M, Niendam, TA, Kopelowicz, A, Cannon, TD (2007). Psychoeducational multi-family group treatment with adolescents at high risk for developing psychosis. Early Intervention in Psychiatry 1, 325332.
Perlis, RH, Ostacher, M, Fava, M, Nierenberg, AA, Sachs, GS, Rosenbaum, JF (2010). Assuring that double-blind is blind. American Journal of Psychiatry 167, 250252.
Phillips, LJ, Nelson, B, Yuen, HP, Francey, SM, Simmons, M, Stanford, C, Ross, M, Kelly, D, Baker, K, Conus, P, Amminger, P, Trumpler, F, Yun, Y, Lim, M, McNab, C, Yung, AR, McGorry, PD (2009). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry 43, 818829.
Preti, A, Cella, M (2010). Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophrenia Research 123, 3036.
Radua, J, Borgwardt, S, Crescini, A, Mataix-Cols, D, Meyer-Lindenberg, A, McGuire, PK, Fusar-Poli, P (2012). Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neuroscience and Biobehavioral Reviews 36, 23252333.
Rietdijk, J, Dragt, S, Klaassen, R, Ising, H, Nieman, D, Wunderink, L, Delespaul, P, Cuijpers, P, Linszen, D, van der Gaag, M (2010). A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials 11, 30.
Schlosser, DA, Miklowitz, DJ, O'Brien, MP, De Silva, SD, Zinberg, JL, Cannon, TD (2011). A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Intervention in Psychiatry 6, 283291.
Schulz, KF, Chalmers, I, Hayes, RJ, Altman, DG (1995). Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 273, 408412.
Schulz, KF, Grimes, DA (2002). Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 359, 781785.
Thornley, B, Adams, C (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 11811184.
Tost, H, Braus, DF, Hakimi, S, Ruf, M, Vollmert, C, Hohn, F, Meyer-Lindenberg, A (2010). Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nature Reviews Neuroscience 13, 920922.
Valentine, JC, Pigott, TD, Rothstein, HR (2010). How many studies do you need? A primer on statistical power for meta-analysis. Journal of Educational and Behavioural Statistics 35, 215247.
van der Gaag, M, Nieman, D, Wunderink, L, Klaassen, R, Rietdijk, J, Dragt, S, Ising, H, Linszen, D (2012 b). The results of a specific CBT intervention in young help-seeking patients with social decline and an ultra-high risk for developing a first episode of psychosis. [Abstracts of the 3rd Biennial Schizophrenia International Research Conference]. Schizophrenia Research 136 (Suppl. 1), S17.
van der Gaag, M, Nieman, DH, Rietdijk, J, Dragt, S, Ising, HK, Klaassen, RM, Koeter, M, Cuijpers, P, Wunderink, L, Linszen, DH (2012 a). Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophrenia Bulletin 38, 11801188.
Woods, SW, Walsh, BC, Saksa, JR, McGlashan, TH (2010). The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophrenia Research 123, 199207.
Xia, J, Adams, CE, Bhagat, N, Bhagat, V, Bhoopathi, P, El-Sayeh, H, Pinfold, V, Takriti, Y (2009). Losing participants before the end of the trial erodes credibility of findings. Psychiatric Bulletin 33, 254257.
Yung, A, McGorry, PD, McFarlane, CA, Jackson, H, Patton, GC, Rakkar, A (1996 a). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin 22, 283303.
Yung, A, Phillips, LB, McGorry, PD (2004). Treating Schizophrenia in the Prodromal Phase. Taylor & Francis: London.
Yung, AR, McGorry, PD, McFarlane, CA, Jackson, HJ, Patton, GC, Rakkar, A (1996 b). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin 22, 283303.
Yung, AR, Nelson, B, Thompson, AD, Wood, SJ (2010). Should a ‘Risk Syndrome for Psychosis’ be included in the DSMV? Schizophrenia Research 120, 715.
Yung, AR, Phillips, LJ, Nelson, B, Francey, SM, PanYuen, H, Simmons, MB, Ross, ML, Kelly, D, Baker, K, Amminger, GP, Berger, G, Thompson, AD, Thampi, A, McGorry, PD (2011). Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. Journal of Clinical Psychiatry 72, 430440.
Yung, AR, Yuen, HP, McGorry, PD, Phillips, LJ, Kelly, D, Dell'Olio, M, Francey, SM, Cosgrave, EM, Killackey, E, Stanford, C, Godfrey, K, Buckby, J (2005). Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Australian and New Zealand Journal of Psychiatry 39, 964971.
Zimbrón, J, Ruiz de Azúa, S, Khandaker, GM, Gandamaneni, PK, Crane, CM, González-Pinto, A, Stochl, J, Jones, PB, Pérez, J (2012). Clinical and sociodemographic comparison of people at high-risk for psychosis and with first-episode psychosis. Acta Psychiatrica Scandinavica. Published online: 20 08 2012 . doi:10.1111/acps.12000.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed